The management of superficial bladder cancer has not changed much during the last years. Transurethral resections with adjuvant intravesical instillation to risk groups have been standard therapy. Cystoscopy and cytology have been used for follow-up. Recently combinations of drugs for instillation and new urinary markers for diagnosis and follow-up have been tested. The role of these new modalities has not been easily judged. Thus the timely advent of guidelines with policy recommendations will play an important part in improving the care of patients in the future.
展开▼
